Mirum Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay approved

Mirum Pharmaceuticals, Inc.

Stockholders elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors with 39.6M, 40.3M, and 32.3M votes for, respectively.
Ratification of Ernst & Young as independent auditor for FY 2026 passed with 49.99M votes for, 5,674 against.
Advisory vote on executive compensation approved with 44.5M votes for, 1.87M against, and 3.6M broker non-votes.
As of record date April 20, 2026, 60,977,841 shares were outstanding and entitled to vote.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Mirum Pharmaceuticals, Inc. shareholders approved Election of three Class I directors at the 2026-06-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-15

Exact text from the filing

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Mirum Pharmaceuticals, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-15 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-15

Exact text from the filing

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-15

Exact text from the filing

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-275811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.